- US-listed companies
- C4 Therapeutics, Inc.
C4 Therapeutics, Inc.CCCC
Market cap
$404.06M
P/E ratio
Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
Cash and cash equivalents | 182 | 76 | 30 | 127 |
Marketable securities, current | - | - | 246 | 127 |
Accounts receivable | 4 | 6 | 1 | 12 |
Prepaid expenses and other current assets | 5 | 11 | 10 | 6 |
Total current assets | 381 | 326 | 288 | 271 |
Marketable securities, non-current | - | - | 61 | 28 |
Property and equipment, net | 3 | 3 | 7 | 7 |
Right-of-use asset | 13 | 32 | 70 | 64 |
Restricted cash | 3 | 3 | 3 | 3 |
Other assets | - | 1 | 2 | 3 |
Total assets | 400 | 507 | 431 | 376 |
Accounts payable | 6 | 5 | 1 | 1 |
Accrued Liabilities and Other Liabilities | 10 | 14 | 20 | 21 |
Deferred revenue, current | - | - | 17 | 15 |
Operating lease liability, current | 1 | 1 | 5 | 5 |
Long-Term Debt, Current Maturities | - | - | 2 | - |
Total current liabilities | 44 | 51 | 45 | 43 |
Deferred revenue, net of current | - | - | 17 | 22 |
Operating Lease, Liability, Noncurrent | 12 | 31 | 71 | 66 |
Long-Term Debt, Excluding Current Maturities | 10 | 11 | 9 | - |
Total liabilities | 119 | 117 | 142 | 130 |
Common Stock, Value, Issued | 0 | 0 | 0 | 0 |
Additional paid-in capital | 465 | 658 | 689 | 775 |
Accumulated other comprehensive loss | 0 | -1 | -4 | -0 |
Accumulated deficit | -184 | -268 | -396 | -528 |
Total stockholders’ equity | 281 | 390 | 289 | 246 |
Total liabilities and stockholders’ equity | 400 | 507 | 431 | 376 |